Show simple item record

dc.contributor.authorCura, Yasmin
dc.contributor.authorPérez Ramírez, Cristina 
dc.date.accessioned2023-05-15T06:54:48Z
dc.date.available2023-05-15T06:54:48Z
dc.date.issued2023-03-17
dc.identifier.citationCura, Y.; Pérez-Ramírez, C.; Sánchez-Martín, A.; Membrive-Jimenez, C.; Valverde-Merino, M.I.; González-Flores, E.; Morales, A.J. Influence of Single-Nucleotide Polymorphisms on Clinical Outcomes of Capecitabine-Based Chemotherapy in Colorectal Cancer Patients: A Systematic Review. Cancers 2023, 15, 1821. [https://doi.org/10.3390/cancers15061821]es_ES
dc.identifier.urihttps://hdl.handle.net/10481/81527
dc.description.abstractThe aim of this systematic review was to provide a comprehensive overview of the literature published in the last decade on the association of single-nucleotide polymorphisms in genes involved in the pharmacodynamic and pharmacokinetic pathways of capecitabine with treatment outcomes among colorectal cancer patients. A systematic search of the literature published in the last 10 years was carried out in two databases (Medline and Scopus) using keywords related to the objective. Quality assessment of the studies included was performed using an assessment tool derived from the Strengthening the Reporting of Genetic Association (STREGA) statement. Thirteen studies were included in this systematic review. Genes involved in bioactivation, metabolism, transport, mechanism of action of capecitabine, DNA repair, and folate cycle were associated with toxicity. Meanwhile, genes related to DNA repair were associated with therapy effectiveness. This systematic review reveals that several SNPs other than the four DPYD variants that are screened in clinical practice could have an impact on treatment outcomes. These findings suggest the identification of future predictive biomarkers of effectiveness and toxicity in colorectal cancer patients treated with capecitabine. However, the evidence is sparse and requires further validationes_ES
dc.description.sponsorshipCo-funded by ERDF funds (EU) from the Instituto de Salud Carlos III (PT13/0010/0039).es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectColorectal canceres_ES
dc.subjectCapecitabinees_ES
dc.subjectPharmacogeneticses_ES
dc.subjectSingle nucleotide polymorphismes_ES
dc.subjectCancers es_ES
dc.titleInfluence of Single-Nucleotide Polymorphisms on Clinical Outcomes of Capecitabine-Based Chemotherapy in Colorectal Cancer Patients: A Systematic Reviewes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.3390/cancers15061821
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
Except where otherwise noted, this item's license is described as Atribución 4.0 Internacional